R+ ≤ 100 mg (n = 38) | R+ 101–200 mg (n = 46) | R+ > 200 mg (n = 48) | P value | |
---|---|---|---|---|
Age, yearsa | 61.2 (13.3) | 64.1 (9.8) | 55.1 (11.6) | 0.001 |
Male, n (%) | 32 (84.2) | 40 (87.0) | 46 (95.8) | 0.18 |
NZ European, n (%) | 20 (52.6) | 25 (54.3) | 16 (33.3) | 0.08 |
Duration of gout years, median (range) | 15.2 (1.2–40.4) | 18.9 (0.16–49.5) | 15.7 (0.37–47.4) | 0.49 |
Baseline serum urate mg/dla | 6.6 (1.6) | 6.6 (1.0) | 7.6 (1.5) | <0.001 |
CrCl ml/mina | 65.0 (29.4) | 56.7 (19.4) | 65.5 (27.9) | 0.19 |
Weight kga, mean (SD) | 99.2 (21.6) | 104.3 (21.4) | 114.3 (20.6) | 0.004 |
Body mass index, kg/m2a | 32.2 (6.3) | 35.2 (7.9) | 36.6 (7.3) | 0.23 |
Baseline allopurinol dosea | 250 (103) | 248 (67) | 316 (123) | 0.002 |
Baseline oxypurinol concentrations, μmol/la | 87.1 (42.0) | 96.9 (47.9) | 90.9 (56.8) | 0.66 |
Co-existing conditions, n (%) | ||||
Obesityb | 20 (52.6) | 35 (76.1) | 41 (85.4) | 0.003 |
Cardiovascular diseasec | 12 (31.6) | 21 (45.7) | 18 (37.5) | 0.41 |
Diabetes mellitus | 11 (28.9) | 16 (34.8) | 16 (33.3) | 0.84 |
Hypertension | 27 (71.1) | 36 (78.3) | 31 (64.6) | 0.34 |
Hyperlipidemia | 25 (65.8) | 25 (54.3) | 25 (52.1) | 0.41 |
Diuretic, n (%) | 12 (31.6) | 22 (47.8) | 18 (37.5) | 0.30 |